Description

Product Description

Surufatinib is a chemically synthesized, orally bioavailable, small-molecule inhibitor designed to target multiple kinases implicated in tumor growth and angiogenesis. Its primary targets are VEGFR1–3, FGFR1, and CSF-1R, making it a versatile research tool for exploring cancer biology, angiogenic signaling, and tumor-immune interactions.

Structurally, Surufatinib contains fluorinated aromatic rings and heterocyclic scaffolds that improve metabolic stability, selectivity, and oral bioavailability. These chemical modifications reduce rapid degradation, allowing sustained intracellular concentrations in experimental assays and preclinical models.

In cellular studies, Surufatinib inhibits VEGFR-mediated endothelial proliferation, migration, and tube formation, suppressing angiogenesis. FGFR1 inhibition disrupts fibroblast growth factor signaling, affecting tumor proliferation and stromal interactions. CSF-1R inhibition modulates tumor-associated macrophage (TAM) activity, allowing research on tumor immune microenvironment interactions.

Preclinical models reveal that Surufatinib reduces phosphorylation of target kinases, decreasing downstream MAPK/ERK and PI3K/AKT signaling, inducing cell cycle arrest, and promoting apoptosis. These effects are useful for exploring tumor growth control, evaluating combination therapies, and studying mechanisms of resistance.

Experimental applications include:

• Signal transduction research: Mapping kinase-dependent signaling networks in tumor and endothelial cells.

• Angiogenesis studies: Assessing endothelial tube formation, migration, and microvessel density.

• Tumor microenvironment modeling: Investigating CSF-1R-mediated macrophage modulation.

• Combination therapy evaluation: Studying synergistic effects with chemotherapeutics, immunomodulators, or other targeted inhibitors.

• Resistance modeling: Monitoring compensatory pathway activation under chronic kinase inhibition.

Its physicochemical properties, including solubility in DMSO and ethanol, stability, and ≥99% purity, ensure reproducibility in mechanistic studies, high-throughput screening, and preclinical oncology research. Surufatinib provides a robust platform for investigating angiogenesis, tumor-stroma interactions, and immune modulation.

Product Specifications

Mechanism of Action

Surufatinib selectively inhibits VEGFR1–3, FGFR1, and CSF-1R, blocking phosphorylation and downstream signaling.

• VEGFR Inhibition: Reduces endothelial proliferation, migration, and tube formation, suppressing angiogenesis and tumor vascularization.

• FGFR1 Inhibition: Disrupts fibroblast growth factor signaling, affecting tumor cell proliferation and stromal interactions.

• CSF-1R Modulation: Reduces tumor-associated macrophage activity, allowing studies on immune microenvironment and tumor-immune interactions.

• Downstream Signaling: Suppression of MAPK/ERK, PI3K/AKT, and STAT3 pathways induces cell cycle arrest and apoptosis in tumor cells.

Experimental applications include combination therapy, angiogenesis assays, tumor microenvironment modeling, and resistance mechanism studies.

Side Effects

In preclinical studies, Surufatinib shows:

• Cell cycle arrest: Typically G1 phase in tumor cells.

• Apoptosis induction: Activation of caspase-dependent and mitochondrial pathways.

• Angiogenesis suppression: Inhibition of endothelial tube formation, proliferation, and migration.

• Immune modulation: Reduced TAM-mediated effects.

• Gene expression modulation: Downregulation of VEGF-A, c-Myc, and cyclin D1.

Laboratory Safety:

• Wear gloves, lab coat, eye protection.

• Handle in fume hood; avoid inhalation and skin contact.

• Store at 2–8 °C, sealed and protected from light and moisture.

• Dispose of residues per institutional hazardous chemical guidelines.

Keywords

Surufatinib, CAS 1308672-74-3, multi-kinase inhibitor, VEGFR inhibitor, FGFR1 inhibitor, CSF-1R inhibitor, anti-angiogenic research, tumor microenvironment, oncology preclinical research, lab-grade small molecule, high-purity research chemical, peptide & chemical supplier China, OEM & bulk production, research compound ≥99% purity.

Shipping Guarantee

All Surufatinib shipments use validated cold-chain logistics to preserve compound integrity. Packages are sealed in moisture-proof containers with secondary protection and continuous temperature monitoring, shipped via express international couriers with full tracking and insurance.

Trade Assurance

We Surufatinib ensure authenticity, verified ≥99% purity, and compliance with HPLC, MS, and NMR standards. Each batch includes a Certificate of Analysis (CoA). Our policy guarantees replacement or refund for any specification deviation.

Payment Support

Flexible global payment options: PayPal, Visa, MasterCard, American Express, T/T, USDT, Bitcoin, Ethereum. All transactions are encrypted and verified.

Disclaimer

All Surufatinib products are for laboratory research only, not for human or veterinary use. They are not drugs, medical devices, or diagnostics. Researchers must follow institutional biosafety and chemical safety guidelines. Information is for scientific reference only.